Key result
Bumetanide comprises <5% of outpatient loop diuretic prescriptions despite superior bioavailability over furosemide.
Why the study?
Bumetanide accounts for less than 5% of outpatient loop diuretic prescriptions and is often relegated to second-line use behind furosemide despite superior oral bioavailability, greater potency, and longer duration of action.
This review highlights the pharmacokinetic advantages of bumetanide over furosemide in heart failure management and explores reasons for its clinical underutilization (<5% of outpatient loop diuretic prescriptions).
Prescribing patterns in HF merit scrutiny for optimization; leaves open barriers to bumetanide adoption and need for randomized outcome trials.
Bumetanide is a valuable loop diuretic utilized in the management of heart failure and chronic kidney disease. Although it accounts for less than 5% of all outpatient loop diuretic prescriptions, its oral bioavailability is highly predictable and generally superior to furosemide, which constitutes over 90% of diuretic prescriptions. Bumetanide is longer-acting and more potent than furosemide; however, many physicians utilize bumetanide as a second-line diuretic when furosemide is ineffective or when intestinal edema limits drug absorption. This review summarizes the pharmacology of bumetanide, its clinical application in patients with heart failure with reduced or preserved ejection fraction, and the factors that contribute to its underutilization despite several pharmacokinetic advantages.
No takes yet. Share an insight, caveat, or question.
Landman et al. (2026) conducted a review in Heart failure (with reduced or preserved ejection fraction) and chronic kidney disease. Bumetanide vs. Furosemide was evaluated. Bumetanide accounts for <5% of outpatient loop diuretic prescriptions vs >90% for furosemide despite superior bioavailability and potency in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: